You are here: Knowledge Bank Press Releases

Press Releases

Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.

To add free press releases please click here.

Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

E-mail Print PDF

Nivolumab is the first PD-1 immune checkpoint inhibitor to receive a positive opinion from the CHMP in advanced non-small cell lung cancer

Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen

E-mail Print PDF

Breakthrough Designation for daclatasvir and sofosbuvir combination is supported by the recently presented ALLY-1 trial in patients with advanced cirrhosis or recurrent hepatitis C (HCV) after liver transplant

Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.™ to Honor Those Affected by Cancer and Increase Awareness of Innovative Immuno-Oncology Research

E-mail Print PDF

• Ready. Raise. Rise. encourages everyone touched by cancer to create a personalized, virtual flag in honor of a loved one and help raise money for cancer advocacy organizations
• New survey shows lack of understanding of Immuno-Oncology and underscores need for greater education on cancer research

Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies

E-mail Print PDF

INDIANAPOLIS, May 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical research institute, will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders.

Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio Across Solid Tumors and Blood Cancers Including Multiple Myeloma

E-mail Print PDF

Pivotal Phase III studies (CheckMate -057 & -017) in both advanced non-squamous and squamous non-small cell lung cancer in which treatment with Opdivo demonstrated superior survival versus chemotherapy with docetaxel in previously-treated patients, to be disclosed

Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities; Increases the Maximum Amount of the Tender Offer

E-mail Print PDF

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that, pursuant to its previously announced cash tender offer for up to $400 million aggregate principal amount (the “tender cap”) of certain of its outstanding debt securities, approximately $534.4 million in aggregate principal amount of the notes listed in the table below were validly tendered and not validly withdrawn on or prior to 5 p.m., New York City time, on May 11, 2015, the early tender date for the tender offer.

Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities

E-mail Print PDF

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for up to $500 million aggregate principal amount of certain of its outstanding debt securities.

Lilly Announces Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016

E-mail Print PDF

INDIANAPOLIS, May 12, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.6 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt. Pursuant to the tender offer, Lilly is offering to purchase, under certain conditions and subject to certain limitations, its 5.55% Notes due 2037, 4.650% Notes due 2044, 5.950% Notes due 2037, 5.50% Notes due 2027, 6.77% Notes due 2036, 7.125% Notes due 2025 and 5.20% Notes due 2017 (collectively, the "notes").

Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies

E-mail Print PDF

INDIANAPOLIS and MAINZ, Germany, May 11, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and BioNTech AG today announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own immune system to attack cancer cells and create possible new treatment options for cancer patients.

Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference

E-mail Print PDF

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Deutsche Bank Global Health Care Conference on Wednesday, May 6, 2015, in Boston. Giovanni Caforio, chief operating officer and CEO-designate, will answer questions about the company at 10:40 a.m. EDT.

Page 1 of 72

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »